



# IAEN

INTERNATIONAL AIDS  
ECONOMICS NETWORK

## 7<sup>th</sup> International AIDS Economics Network Pre-Conference Meeting

July 20-21, 2012  
Washington DC

Hosted with generous support from:





## International AIDS Economics Network Pre-Conference Meeting

Location: Center for Global Development  
1800 Massachusetts Ave, NW  
Washington DC

### Friday July 20, 2012

8:00 am – 8:30 am	<b>Registration &amp; Continental Breakfast</b> Location: Main Conference Hall, Floor I
8:30 am – 8:40 am	<b>Opening Remarks</b> <b>Nancy Birdsall</b> , <i>President, Center for Global Development</i>
8:40 am – 8:50 am	<b>Welcome to the International AIDS and Economics Network (IAEN) Pre-Conference</b> <b>Dr. Steven Forsythe</b> , <i>President, International AIDS Economics Network</i>
8:50 am – 9:00 am	<b>Opening Remarks</b> <b>Roxana Rogers</b> , <i>Director, Office of HIV/AIDS (OHA), Bureau of Global Health, USAID</i>
9:00am – 9:30 am	<b>Keynote Speech</b> <b>Ambassador Eric Goosby</b> , <i>United States Global AIDS Coordinator for the United States President's Emergency Plan for AIDS Relief (PEPFAR)</i>
9:30 am – 9:50 am	<b>Coffee &amp; Tea Break</b>
9:55 am – 11:10 am	<b>Plenary Session # 1</b> Chair: Sydney Rosen, <i>Associate Professor, Boston University Center for Global Health and Development; Health Economics and Epidemiology Research Office (HE<sup>2</sup>RO)</i>
	<p><b>“Cost Analysis of a large scale harm reduction intervention over 5 years for Injecting Drug users (IDUs) in Manipur, a complex implementation environment in India.”</b> Dr. Sudha Chandrashekar, <i>Associate Professor, St. John's Research Institute, Research Fellow, Department of Global Health and Development London School of Hygiene and Tropical Medicine</i></p> <p><b>“Evaluating the Costs of Medication Assisted Therapy in Georgia,”</b> Irma Kirtadze, <i>M.D., Addiction Research Center Alternative Georgia.</i></p> <p><b>“Scaling-Up Male Circumcision in Tanzania Yields Cost Benefits for HIV Prevention,”</b> Veena Menon, <i>Senior Policy Analyst, Futures Group</i></p> <p><b>“Strategies to facilitate timely and rigorous impact evaluation of large-scale HIV interventions,”</b> Daniel O'Farrell, <i>Partnership Officer, Riders for Health</i></p>
11:15 am – 12:30 pm	<b>Plenary Session # 2</b> Chair: Paurvi Bhatt, <i>Senior Director, Strategic Health Initiatives at Levi Strauss and Co.</i>
	<p><b>“The Cost-Effectiveness of Adding a Third HIV Test in Routine HIV Testing to Reduce the Frequency of False Positive Test Results in Sub-Saharan Africa,”</b> Elliott Marseille, <i>Dr.PH, MPP, Health Strategies International</i></p> <p><b>“The cost-effectiveness of maternal and infant antiretroviral regimens to prevent vertical HIV transmission in Malawi,”</b> Paul Revill, <i>Centre for Health Economics, University of York</i></p> <p><b>“The cost-effectiveness of early detection and adequate monitoring of HIV/AIDS patients in Mexico,”</b> Arantxa Colchero, <i>PhD., National Institute of Public Health</i></p>
12:40 pm – 1:40 pm	<b>Lunch</b> Location: Room 1004/1006, Floor I

1:45 pm – 3:00 pm	<b>Concurrent Sessions</b>
<b>Concurrent Session A: Resource Allocation</b> Chair: Dr. Farley Cleghorn, Senior Vice President and Chief Technical Officer, Futures Group	<p><b>“Costing study of national HIV care and treatment program in Viet Nam: to optimize resource allocation and to deliver sustainable and quality services”</b> Mrs. Duong Thuy Anh, <i>Vietnam Authority Of HIV/AIDS Control, Ministry Of Health</i></p> <p><b>“A portfolio approach to HIV control in South Africa”</b>, Elisa F. Long, <i>Assistant Professor, Yale School of Management</i></p> <p><b>“Spending On Prevention Activities In The SADC Region – Are The Trends and Priorities Within an Investment Framework?”</b> Rosette Kyomuhangi Khiga, <i>Senior Researcher, Centre for Economic Governance and AIDS in Africa</i></p> <p><b>“ART Guideline Changes and the Potential Impacts on Program Sustainability in Botswana,”</b> Peter M. Stegman, <i>Senior Economist &amp; Managing Director of the Southern Africa Office, Futures Institute</i></p>
<b>Concurrent Session B: Sustainability</b> Chair: John Stover, President of Futures Institute	<p><b>“Financial Sustainability of the Response to HIV and AIDS in South Africa: Comparing the Estimated Costs of the New South African National Strategic Plan with Projected Estimates of Available Funds – Exploring Alternative funding options,”</b> Teresa Guthrie MPH, <i>Executive Director, Center for Economic Governance and AIDS in Africa (CEGAA)</i></p> <p><b>“Evaluating the Costs of Implementing a More Sustainable Response: A Study of PEPFAR Support to Kenya’s PMTCT Program, 2005-2010,”</b> Dr. Kioko Urbanus Mutuku, <i>Health Economist, University of Nairobi</i></p> <p><b>“Assessment process for human resources for health planning toward more sustainable antiretroviral therapy (ART) treatment and HIV counseling and testing (HCT) services,”</b> Wendy Wong, <i>Analyst, Abt Associates</i></p> <p><b>“Assuring the delivery of third-line ART in Brazil: Policy Issues and Perspectives”</b> Constance Marie Meiners-Chabin, <i>Technical Adviser, Sustainability, Management and Cooperation Division, STD, AIDS and Viral Hepatitis Department, Secretariat for Health Surveillance, Ministry of Health, Brazil</i></p>
<b>Concurrent Session C: Cost of Treatment</b> Chair: Damian Walker, PhD, Senior Program Officer, Cost-Effectiveness /Integrated Delivery, Global Development, Bill and Melinda Gates Foundation	<p><b>“Antiretroviral Therapy in Zambia: Costs, Patient Outcomes and Implications for further scale-up”</b> Mike Hanlon, <i>Lecturer, Institute for Health Metrics and Evaluation, University of Washington, USA</i></p> <p><b>“Taking ART to Scale: Determinants of the Cost and Cost-Effectiveness of Antiretroviral Therapy in 45 Clinical Sites in Zambia,”</b> Elliott Marseille, <i>Dr.PH, MPP, Health Strategies International</i></p> <p><b>“The cost of scaling-up Antiretroviral Treatment: a costing study in 161 representative facilities in Ethiopia, Malawi, Rwanda, and Zambia,”</b> Elya Tagar, <i>Director, Global HIV Financing, Clinton Foundation</i></p> <p><b>“Explaining variation in the average cost of antiretroviral treatment: Policy and environmental determinants of the cost of ART in Africa,”</b> Mead Over, <i>Senior Fellow, Center for Global Development</i></p> <p><b>"Site Maturity and Patient Volume are Strong Predictors of HIV Treatment Costs in Resource Limited Settings: Results of a 6 Country Study",</b> Nicolas Menzies, <i>PhD Candidate, Center for Health Decision Science, Harvard School for Public Health</i></p>
3:00 pm – 3:20 pm	<b>Coffee &amp; Tea Break</b> Location: Main Conference Hall, Floor 1
3:25 pm – 4:40 pm	<b>Concurrent Sessions</b>
<b>Concurrent Session D: Costing</b> Chair: Sergio Bautista-Arredondo, Head of the Health Economics Division, National Institute of Public Health	<p><b>“A new approach to costing HIV interventions: Using project records from the International HIV/AIDS Alliance coalition of organizations in West Africa,”</b> Amidou Kabore, <i>Master II in Project Management, Project Management, Costing and Spending Assessment Consultant, "Consultancy and Investment Office" Manager, Burkina Faso</i></p> <p><b>“A Quality Review Process for HIV Prevention Costing Studies in Developing Countries,”</b> Willyanne DeCormier Plosky, <i>Policy Analyst, Futures Institute &amp; Lori Bollinger, Vice President and Senior Economist, Futures Institute</i></p> <p><b>“Costing the HIV/AIDS Supply Chain in Ghana,”</b> Damaris Forson, <i>Program Officer for HIV/AIDS, John Snow Inc., USAID   DELIVER PROJECT, Ghana</i></p> <p><b>“Rush to Judgement: Confounding in STI-HIV Prevention Trials,”</b> Larry Sawers, <i>Professor, Department of Economics, American University</i></p>
<b>Concurrent Session E: Economic Impact</b> Chair: Alan Whiteside, Director, Health Economics & HIV/AIDS Research Division (HEARD), University of KwaZulu-Natal	<p><b>“An Investigation of the Health and Economic Impact of HIV/AIDS on Malawi Households: A Cohort Study in Mangochi District,”</b> Felix Allan Makwinja, <i>M’Bawa Development Consult</i></p> <p><b>“Comparative economic positions of orphan, non-orphan and mixed households: Findings from round 3 of the Amajuba District Study in KwaZulu-Natal, South Africa,”</b> Gavin George, <i>Senior Researcher, Health Economics &amp; HIV/AIDS Research Division (HEARD, University of KwaZulu-Natal</i></p> <p><b>“Economic spillover effects of ART on rural South African households,”</b> Jacob Bor, <i>Doctoral Candidate in Health Economics, Department of Global Health and Population, Harvard School of Public Health</i></p> <p><b>“Long-run effects of ART on employment in rural South Africa: evidence from a population cohort,”</b> Till Bärnighausen <i>Associate Professor of Global Health, Harvard School of Public Health &amp; Senior Epidemiologist, Africa Centre for Health and Population Studies</i></p>

<p><b>Concurrent Session F: Treatment as Prevention</b></p> <p>Chair: Amanda Glassman, Director of Global Health Policy, Center for Global Development</p> <p>Discussant: David Wilson, Director of Global AIDS Program, World Bank</p>	<p>“<b>Cost-benefit analysis of investing in AIDS treatment</b>”, Geoff Garnett, <i>Professor, Imperial College, United Kingdom</i></p> <p>“<b>Re-assessing the costs of HIV treatment: estimation of external benefits of ART and their contribution to sustainability</b>”, Nalinee Sangrujee, Ph.D, MPH, <i>Senior Economist, Lead Health Economics and Finance Team, Global AIDS Program, The Centers for Disease Control and Prevention</i></p> <p>“<b>Modelling cost of ART for prevention</b>”, Lawrence Long, <i>Deputy Division Head, Health Economics and Epidemiology Research Office (HE<sup>2</sup>RO) &amp; Mead Over, Senior Fellow, Center for Global Development</i></p> <p>“<b>ART Therapy awareness and risky sexual behavior</b>”, Damien De Walque, <i>Senior Economist, The World Bank - Development Research Group</i></p>
<p><b>5:00 pm – 5:15 pm</b></p>	<p><b>Sponsor Presentations</b> Location: Main Conference Hall, Floor I</p>
	<p><b>The United States President’s Emergency Plan for AIDS Relief:</b> Nalinee Sangrujee, Ph.D, MPH, <i>Senior Economist, Lead Health Economics and Finance Team, Global AIDS Program, The Centers for Disease Control and Prevention &amp; Elan B Reuben, Technical Advisor, Costing Office of HIV/AIDS, Bureau for Global Health, U.S. Agency for International Development, USAID</i></p> <p><b>The Rush Foundation:</b> Marina Galanti, <i>President, The Rush Foundation</i></p> <p><b>Abbott Laboratories:</b> Matt Hamada, Sr. <i>Product Manager, Abbott International Marketing, Virology.</i></p> <p><b>Health Economics and HIV/AIDS Research Division (HEARD):</b> Alan Whiteside, <i>Director, Health Economics &amp; HIV/AIDS Research Division (HEARD), University of KwaZulu-Natal</i></p>
<p><b>5:15 pm – 5:30 pm</b></p>	<p><b>Achieving an AIDS Transition</b> Mead Over, <i>Senior Fellow, Center for Global Development</i></p>
<p><b>5:30 pm – 7:30 pm</b></p>	<p><b>Welcome Reception at Center for Global Development</b> Location: Third Floor</p>

## Saturday July 21, 2012

<p><b>9:00 am – 9:20 am</b></p>	<p><b>Continental Breakfast</b> Location: Main Conference Hall, Floor I</p>
<p><b>9:20am – 9:50 am</b></p>	<p><b>Keynote Speech</b> <b>Dr. Stefano Bertozzi</b>, <i>Director HIV, Global Health Program, Bill and Melinda Gates Foundation</i></p>
<p><b>9:50 am -10:00 am</b></p>	<p><b>Coffee &amp; Tea Break</b></p>
<p><b>10:00 am – 11:15 am</b></p>	<p><b>Plenary Session # 3</b> Chair: Eileen Stillwaggon, <i>Professor of Economics and Harold G. Evans-Eisenhower Professor, Gettysburg College</i></p>
	<p>“<b>The cost of inpatient treatment for multi-drug resistant tuberculosis in South Africa,</b>” Kathryn Schnippel, <i>Senior Researcher, Health Economics and Epidemiology Research Office, University of the Witwatersrand</i></p> <p>“<b>Risk Management in HIV/AIDS: ethical and economic issues associated with restricting HAART access only to adherent patients,</b>” Dr. Richard Chawana, <i>University of the Witwatersrand</i></p> <p>“<b>Model Based Consensus on the Impact of an RV144-like HIV Vaccine in Diverse Epidemic Settings,</b>” <i>Elisa F. Long, Assistant Professor, Yale School of Management</i></p>
<p><b>11:20 am – 12:40 pm</b></p>	<p><b>Plenary Session # 4</b> Chair: Robert Hecht, PhD, <i>Managing Director, Results for Development Institute</i></p>
	<p>“<b>Is treatment-as-prevention the new game-changer? Costs and Effectiveness,</b>” Till Bärnighausen <i>Associate Professor of Global Health, Harvard School of Public Health &amp; Senior Epidemiologist, Africa Centre for Health and Population Studies</i></p> <p>“<b>Evaluating Conditional Cash Transfers for HIV/STI Prevention in Rural Tanzania: 1-Year Post-Intervention Follow-up,</b>” Damien De Walque, <i>Senior Economist, The World Bank - Development Research Group</i></p> <p>“<b>Disability Grant terminations and virologic and immunologic response to ARV treatment,</b>” Professor Frederik Booysen, <i>Department of Economics, University of the Free State</i></p>
<p><b>12:40 pm – 1:40 pm</b></p>	<p><b>Lunch</b> Location: Room 1004/1006, Floor I</p>
<p><b>1:45 pm–2:00 pm</b></p>	<p><b>International AIDS Economics Network: Past, Present and Future</b> Location: Main Conference Hall, Floor I</p>

2:05 pm – 3:25 pm	<b>Concurrent Sessions</b>
<b>Concurrent Session G: Treatment</b> Chair: TBD	<p><b>“Outcomes and outpatient costs of pediatric ART in Zambia,”</b> Callie Scott, <i>Research Fellow, Zambia Center for Applied Health Research and Development, Boston University Center for Global Health and Development</i></p> <p><b>“The impact of antiretroviral therapy on economic outcomes for South African patients: five-year follow-up and attrition analysis,”</b> Sydney Rosen, <i>Associate Professor, Boston University Center for Global Health and Development; Health Economics and Epidemiology Research Office (HE<sup>2</sup>RO)</i></p> <p><b>“Does HIV Treatment Stimulate Negative Risk Compensation? A Field Experiment in South Africa,”</b> Plamen Nikolov, <i>PhD Candidate, Harvard University, Affiliate, Institute for Quantitative Social Science and The Weatherhead Center for International Affairs</i></p>
<b>Concurrent Session H: Prevention</b> Chair: Marina Galanti, <i>President, The Rush Foundation</i>	<p><b>“Value for Money – challenges to current paradigms and suggestions for improvement,”</b> Dr. Anthony Kinghorn, <i>Technical Director: Health and Development Africa</i></p> <p><b>“Economic evaluation of HIV vaccination: current practice and broadened perspectives,”</b> Till Bärnighausen <i>Associate Professor of Global Health, Harvard School of Public Health &amp; Senior Epidemiologist, Africa Centre for Health and Population Studies</i></p> <p><b>“Conditional Economic Incentives to Reduce Sexually Transmitted Infections And HIV Risks Among Male Sex Workers: Rationale and Baseline Results from a Randomized Pilot in Mexico City,</b> Omar Galarraga, <i>Ph.D., Assistant Professor, Brown University, Health Services, Policy &amp; Practice (Health Economics)</i></p>
<b>Concurrent Session I: Cost of Treatment</b> Chair: Charlotte M. Zikusooka <i>Senior Consultant, Research and Mentoring, HealthNet Consult</i>	<p><b>“Should the lack of and the poor quality of information on HIV/AIDS unit costs raise concerns about resource allocation inefficiency in Sub Saharan Africa,”</b> Grace Kabaniha, <i>Health Economist, Researcher, HealthNet Consult, Uganda</i></p> <p><b>“Trends of resource allocation for HIV/AIDS in low -income countries: Are there inefficiencies?”</b> Grace Kabaniha, <i>Health Economist, Researcher, HealthNet Consult, Uganda</i></p> <p><b>“Challenges of adapting the standard National AIDS Spending Assessment methodology in some African countries: a case study of Uganda,”</b> Christabell Abewe, <i>Researcher, HealthNet Consult, Uganda</i></p>
3:25 pm – 3:45 pm	<b>Coffee &amp; Tea Break</b> Location: Main Conference Hall, Floor I
3:45 pm – 5:05 pm	<b>Concurrent Sessions</b>
<b>Concurrent Session J: Cost Effectiveness</b> Chair: Dr. Steven Forsythe, <i>President, International AIDS Economics Network &amp; Director, Health Policy Initiative Costing Task Order, Futures Institute</i>	<p><b>“Cost Effectiveness Analysis of PMTCT service delivery modalities in Addis Ababa (Using Decision Models),”</b> Elias Asfaw Zegeye, <i>Assistant Researcher II, Health Economist, Ethiopian Health and Nutrition Research Institute (EHNRI)</i></p> <p><b>“A systematic review of the cost-effectiveness of Harm Reduction for IDUs – how good is the evidence?”</b> Dr. Lorna Guinness, <i>Lecturer (Health Economics), Faculty of Public Health &amp; Policy, London School of Hygiene &amp; Tropical Medicine &amp; Visiting Research Fellow, Australian National University</i></p> <p><b>“The Costing of HIV Testing and Counseling in Botswana: Capturing Cost and Effectiveness Data for Multiple Service Delivery Models,”</b> Peter M. Stegman, <i>Senior Economist &amp; Managing Director of the Southern Africa Office, Futures Institute</i></p>
<b>Concurrent Session K: Scaling Up: Cost and Efficiency</b> Chair: Dr. Stefano Bertozzi, <i>Director, HIV, Global Health Program, Bill and Melinda Gates Foundation</i>  Discussant: Damian Walker, <i>PhD, Senior Program Officer, Cost-Effectiveness /Integrated Delivery, Global Development, Bill and Melinda Gates Foundation</i>	<p><b>“Cost and efficiency analysis of the Avahan HIV Prevention programme for high risk groups in India,”</b> Dr. Sudha Chandrashekar, <i>Associate Professor, St. John’s Research Institute, Research Fellow, Department of Global Health and Development London School of Hygiene and Tropical Medicine</i></p> <p><b>“How does integration impact the costs and efficiency of delivering HIV Services?”</b> Carol Dayo Obure, <i>Research Fellow, Department of Global Health and Development, London School of Hygiene and Tropical Medicine</i></p> <p><b>“Value for money of structural interventions: going beyond HIV-only cost-effectiveness analysis,”</b> Michelle Remme, <i>Research Fellow, Department of Global Health and Development, London School of Hygiene and Tropical Medicine</i></p> <p><b>“Introducing new TB diagnostics for those living with HIV: consequences for the South African health budget,”</b> Anna Vassall, <i>Lecturer Economics of HIV, Department of Global Health and Development, London School of Hygiene and Tropical Medicine</i></p>
<b>Concurrent Session L: Out-of-Pocket Expenditures</b> Chair: Carlos Avila <i>Principal Associate, Senior Health Economist Abt Associates</i>	<p><b>“Out-of-pocket payments in HIV treatment in Tanzania: Evidence from ten sites,”</b> Andres Berruti, <i>Senior Economist Health Economics and Finance Team, Health Economics, Systems and Integration Branch, CDC/Division of Global HIV/AIDS</i></p> <p><b>“Out of Pocket Expenditures and Financial Protection of HIV Services,”</b> Douglas M Glandon, <i>MPH, Resource Tracking Strategy Lead Health Systems 20/20, Abt Associates Inc.</i></p> <p><b>“Out-of-pocket costs for patients receiving HIV care and treatment in Kenya,”</b> Anna Krivelyova, <i>Principal, ICF International</i></p>
5:10 pm – 5:30 pm	<b>Closing Remarks</b> Dr. Steven Forsythe, <i>President, International AIDS Economics Network</i> Location: Main Conference Hall, Floor I